Medtronic plc (MDT) announced Tuesday it's moving forward with plans to acquire CathWorks, an Israeli medical device company that's been developing AI-powered tools for heart care. The deal values the privately held firm at up to $585 million, with additional earn-out payments possible down the road.
This isn't exactly a surprise romance. Medtronic and CathWorks have been working together since 2022 through a strategic partnership that included co-promotion rights for CathWorks' flagship product, the FFRangio System, across the U.S., Europe, and Japan. Now Medtronic is making it official by bringing the whole operation in-house.
What CathWorks Actually Does
CathWorks specializes in coronary digital health, which is a fancy way of saying they help doctors figure out which blockages in your heart arteries actually need treatment. The key metric here is fractional flow reserve, or FFR, which helps physicians identify which lesions truly cause ischemia—meaning they're actually restricting blood flow enough to matter.
Here's where it gets interesting: The CathWorks FFRangio System combines artificial intelligence with advanced computational science to deliver FFR values along the entire coronary tree, all derived from angiography. Translation: It can assess blood flow problems without needing some of the more invasive traditional methods.
The system also provides intraprocedural optimization tools, including assessment of how well a treatment worked and interactive sizing tools to measure lesion dimensions. The practical upshot? Doctors can make better decisions about who actually needs a percutaneous coronary intervention (PCI) and who doesn't, avoiding unnecessary procedures for patients who won't benefit.
Deal Timeline and Financial Impact
The acquisition is currently waiting for clearance from the Federal Trade Commission. Medtronic expects that process to wrap up by the end of its fiscal year 2026. Until then, the two companies will keep operating independently.
Once the deal closes, CathWorks will become part of Medtronic. The company says the acquisition should be immaterial to its fiscal 2027 GAAP and adjusted earnings per share, and neutral to accretive after that—corporate speak for "it won't hurt our numbers and might help them."
Recent Medtronic Developments
A William Blair analyst upgraded Medtronic in January, pointing to several new product launches gaining momentum. But it hasn't all been smooth sailing—back in December 2025, the Food and Drug Administration flagged that Medtronic had notified customers to remove certain Left Heart Vent Catheters from use and sale due to safety concerns. These catheters are used to vent the left heart during cardiopulmonary bypass procedures lasting up to six hours.
Medtronic shares were trading up 1.86% at $104.62 on Tuesday following the acquisition announcement.
